CAPTRUST Financial Advisors
SIOX

CAPTRUST Financial Advisors’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,018
Closed – – 4486
2022
Q2 		$0 Hold
1,018
– – ﹤0.01% 5247
2022
Q1 		$1K Hold
1,018
– – ﹤0.01% 4801
2021
Q4 		$1K Hold
1,018
– – ﹤0.01% 4683
2021
Q3 		$2K Hold
1,018
– – ﹤0.01% 4328
2021
Q2 		$3K Buy
1,018
+1,000
+5,556% +$2.49K ﹤0.01% 4081
2021
Q1 		$0 Hold
18
– – ﹤0.01% 4529
2020
Q4 		$0 Hold
18
– – ﹤0.01% 3562
2020
Q3 		$0 Hold
18
– – ﹤0.01% 3309
2020
Q2 		$0 Buy
+18
New +$58 ﹤0.01% 2927

Other funds holding SIOX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TVWM
Tower View Wealth Management Shorewood, Wisconsin $227M AUM 41.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $1.14B AUM 48.66% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

CAPTRUST Financial Advisors's SIOX Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q3 2022, closing a stake of 1,018 shares.

CAPTRUST Financial Advisors first reported a position in SIOX in Q2 2020 and held it in 9 quarters. The position peaked at $3K in Q2 2021. 40 funds tracked by Wall St. Rank hold SIOX as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 1,018 Sio Gene Therapies Inc. Common Stock shares in Q3 2022.
  • CAPTRUST Financial Advisors first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2020 and held it in 9 quarters.
  • CAPTRUST Financial Advisors's Sio Gene Therapies Inc. Common Stock position peaked at $3K in Q2 2021.
  • 40 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.